Pfizer Inc.
Pfizer Inc. sells prescription medicines and vaccines to healthcare providers, public health organizations, and governments via direct sales, wholesalers, and strategic partnerships by researching, developing, manufacturing, and distributing innovative biopharmaceutical products across a broad therapeutic range.
LOCKED
Market: NormalKey Catalysts & Risks
The dominant negative catalyst is the loss-of-exclusivity wave management has flagged for 2026 through 2028, which compresses revenue from several large brands, raises the importance of cost savings and keeps leverage elevated through the transition. On the upside, the obesity programme is the main re-rating candidate: Pfizer is running a broad set of late-stage studies for its Metsera-derived monthly GLP-1 and amylin combinations, with first approval targeted around 2028 and interim readouts expected before that, so data flow will drive sentiment well before revenue arrives. Oncology readouts are the second lever, with late-stage prostate and bladder cancer data and label expansions potentially validating the acquired platform and supporting management's stated ambition to return to growth toward the end of the decade. Regulatory and policy events are ambiguous: the 340B pilot beginning in early 2027 includes Pfizer products, and the most-favoured-nation and TrumpRx framework, alongside a temporary tariff exemption, reshape US pricing and manufacturing economics in ways management describes as broadly manageable but only marginally positive at the net level. Capital returns are a secondary swing factor, since management has signalled the dividend will be maintained and eventually grow, with buybacks revisited only after de-levering, so any resumption would signal greater confidence in the post-exclusivity profile.
The central structural risk is the loss-of-exclusivity cliff across 2026 to 2028, which erodes the economics of several large mature brands and makes the company dependent on new and acquired products, cost savings and pipeline execution to replace that cash flow. Pricing regulation is a second structural exposure, as the most-favoured-nation agreement and the new direct-to-consumer channel reduce US pricing on Medicaid and new launches, limiting the ability to offset volume or exclusivity pressure with price over the medium term. These factors matter for the 12 to 36 month equity case because they cap operating leverage even if cost programmes and new launches land, and they keep the balance sheet more leveraged through the transition, leaving less cushion for setbacks in obesity or oncology.
Research refreshed: 2nd of October 2026
KPIs and Peer Benchmarks
| EV | P/E | Net Debt/EBIT | Revenue Growth | |
|---|---|---|---|---|
| AbbVie Inc. (ABBV) | 529B | 74.04 | 3.40 | 8.6% |
| Amgen Inc. (AMGN) | 261B | 24.85 | 3.42 | 9.9% |
| AstraZeneca… (AZN) | 274B | 23.65 | 1.98 | 8.6% |
| Bristol-Mye… (BMY) | 159B | 13.48 | 2.47 | -0.2% |
| Gilead Scie… (GILD) | 207B | N.M. | N.M. | 2.4% |
| GSK plc (GSK) | 115B | 14.96 | 1.89 | 4.1% |
| Johnson & J… (JNJ) | 646B | 29.60 | 1.09 | 6.0% |
| Eli Lilly a… (LLY) | 1.14T | 38.80 | 1.16 | 44.7% |
| Merck & Co.… (MRK) | 403B | 114.52 | 4.26 | 1.2% |
| Novo Nordis… (NVO) | 181B | 9.49 | 0.67 | 6.4% |
| Novartis AG (NVS) | 308B | 21.31 | 2.54 | 6.0% |
| Sanofi (SNY) | 115B | 21.65 | 1.71 | 5.5% |
| Pfizer Inc. (PFE) | 221B | 36.73 | 3.89 | -1.6% |
AI Opinion
Fundamentals
Non-COVID recovery supports a selective BUY: Q2 underlying operational revenue grew 5%, launched/acquired products grew 18%, and Padcev grew over 20%. These earnings-call disclosures strengthen the recovery case beyond flat TTM revenue, but do not establish company-wide organic growth. Seagen execution and cost savings can support near-term repricing; 2026-2028 patent expirations, clinical failures and declining cash generation constrain conviction.
Peer Comparison
Peer fair value of $34.47 implies 22.6% price upside, but Pfizer ranks last among 11 quantified peers on combined growth and quality. That discount is partly justified. Anchor the base case to the lower historical fair value of $31.92 rather than assuming full peer convergence.
Macro Environment
Healthcare demand is relatively insulated from discretionary spending, but no quantified current macro-to-sales relationship is established. US revenue exposure of 58.9% makes pricing and reimbursement policy material risks. The 5.24% Treasury yield creates a valuation hurdle and reduces the appeal of the 6.1% dividend yield. Mixed sector breadth is context, not a Pfizer-specific sell signal; company execution matters more than unsupported inflation or FX assumptions.
Key Metrics
EV/EBITDA is 9.54x versus an 11.20x historical median; historical fair value implies 13.5% price upside. Price is approximately 9.7x the $2.90 midpoint of FY2026 adjusted EPS guidance. Operating margin is 25.08%, FCF margin 17.25%, ROIC 9.33%, and FCF yield approximately 6.8%. A maintained $1.72 dividend adds 6.1%, producing approximately 19.6% potential total return at historical fair value, conditional on rerating and dividend continuity.
Insider Activity
August CEO and director purchases totaled approximately $2.96M, including a CEO position increase of 9.6%, substantially exceeding smaller officer sales. Slightly bullish confirmation only: no trades occurred in the latest 30 days, and the buying does not establish a catalyst or valuation floor.
Income Statement
TTM revenue declined 0.21%, operating expenses rose 12.86%, and operating income fell 15.44%. The call provides stronger forward evidence: Q2 adjusted EPS was $0.77, adjusted operating margin was 35%, and FY2026 adjusted EPS guidance remained $2.80-$3.00 despite a $0.10 IPR&D headwind. The $4.3B noncash impairment explains much of the GAAP weakness but also reflects failed asset expectations. Use the revised $60.5B-$62.5B revenue range rather than the internally inconsistent stated midpoint increase; COVID guidance fell $1B to approximately $4B.
Cash Flow
TTM FCF of $10.99B fell 11.68%; dividends consumed 89.1%, leaving only $1.20B of coverage headroom. Working-capital outflows remain material. The call reports Q2 OCF of $3.45B versus $835M in the fundamental report; this unresolved discrepancy prevents a confident quarterly cash-recovery conclusion. The $2.6B final repatriation-tax payment offers potential cash normalization, but dividend maintenance requires sustained coverage, not management assurances alone.
Balance Sheet
Calculated net debt increased 8.5% to $54.94B while cash and short-term investments fell 26.0% to $8.26B. Goodwill and intangibles represent 58.9% of assets. Management reported 2.7x leverage and expects it to remain stable or modestly higher through the loss-of-exclusivity transition, limiting deleveraging and buyback upside despite $1.65B of ViiV exit proceeds.